Tackling Endocrine Resistance in Breast Cancer

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

In June 2025, the FDA approved pembrolizumab in the same indication for HNSCC.2

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP

August 11th 2025

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD

Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.

It was noted that in those with a CTFI of more than 3 months but less than or equal to 6 months, a “promising” number of durable responses was observed.

Adagrasib Boosts PFS, Responses vs Docetaxel in KRAS G12C+ NSCLC

Patients with extensive-stage small cell lung cancer experienced a median PFS and OS of 4.5 months and 7.2 months with anlotinib plus irinotecan.

Related Content

Russ Conroy

Navigating the Evolving Second-Line Landscape of Metastatic Urothelial Carcinoma

Findings from the KRYSTAL-12 trial support adagrasib as a treatment option for those with disease progression on prior chemotherapy and immunotherapy.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

Health Canada Approves Pembrolizumab/Surgery in Locally Advanced HNSCC

The latest in first- and second-line therapies for bladder cancer, including trial data, AE management, and the role of molecular testing, were discussed in the latest Oncology Decoded podcast.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Results from the phase 3 KEYNOTE-689 trial supported the agency’s approval of the pembrolizumab/surgery regimen in PD-L1–positive head and neck cancer.

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP

August 11th 2025

Safeguarding Vulnerability: COVID-19’s Impact on Immunocompromised Patients With Cancer

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Viviana Cortiana, MS4;Maduri Balasubramanian, MD;Jade Gambill, BS;Diksha Mahendru, MD;Kennedy Itodo, MD;Chandler H. Park, MD, MS, FACP;Yan Leyfman, MD

Anlotinib/Irinotecan Shows Promise, Durable Responses in ES-SCLC

Immunocompromised individuals face ongoing COVID-19 risks despite vaccination, highlighting the need for tailored public health strategies and innovative therapies.